French Trial Tragedy: Who Says What Data Should Be Published?
This article was originally published in Scrip
Executive Summary
While French government inspectors pore over the results of their recent visit to the premises of Biotrial, the CRO that ran the ill-fated Phase I study with the FAAH inhibitor BIA 10-2474, the regulatory agency ANSM has revealed that the product's developer, Bial, has opposed the publication of the preclinical documentation on the drug.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.